A man in his early forties, marginally overweight, sleeping poorly, exercising less than he used to, walks into a testosterone replacement therapy clinic in suburban Phoenix and leaves two hours later with a prescription, a phlebotomy schedule, and a monthly subscription that will cost him roughly $300 for the next several years. The clinical evaluation he received is more thorough than the ten-minute primary care visit that produced no actionable diagnosis last spring. The therapeutic intervention he is receiving has clinical evidence behind it for some patient populations and considerably less evidence for others. Whether he is among the populations for whom the evidence supports treatment is a question the visit was not structured to answer rigorously, and the commercial model of the clinic does not particularly reward asking.
The TRT clinic sector emerged in the early 2010s in close coordination with the marketing campaigns that AbbVie and several other manufacturers conducted around testosterone gel products. The ‘Low T’ framing—which converted a heterogeneous set of symptoms into a single named condition treatable with a specific class of products—proved exceptionally effective at expanding the diagnosed prevalence of hypogonadism. Prescriptions for testosterone in the United States more than tripled between 2001 and 2011 before plateauing and partially declining in the mid-2010s after FDA labeling changes warned about cardiovascular risks. The clinic sector that grew up around the marketing boom outlasted the marketing’s peak and has, in the past decade, professionalized considerably.
What distinguishes the contemporary TRT clinic from its 2010s predecessor is the breadth of services offered and the sophistication of the patient targeting. Modern operations rarely market themselves narrowly as testosterone clinics. They are men’s health practices, hormone optimization centers, or longevity medicine clinics. The testosterone prescription is one offering within a broader portfolio that may include peptide therapies, weight management protocols, sleep medicine consultations, and various adjacent services. The patient base is predominantly cash-pay, predominantly affluent, and increasingly insulated from the conventional insurance reimbursement system.
The clinical evidence for testosterone therapy in men with clear hypogonadism—total testosterone below 300 ng/dL, symptoms of androgen deficiency, no contraindications—is reasonably strong. The TRAVERSE trial, published in NEJM in 2023, established that testosterone replacement in men with biochemical hypogonadism and elevated cardiovascular risk did not increase major cardiovascular events compared with placebo, resolving a decade of regulatory uncertainty about safety. The trial’s confirmation of cardiovascular safety has been important for the legitimacy of the field and has, predictably, supported continued expansion of the clinic sector.
What TRAVERSE did not address, and what the broader clinical evidence does not strongly support, is treatment of men whose total testosterone is in the 300-450 ng/dL range, whose symptoms are nonspecific, and whose decline in androgen levels reflects normal aging rather than a pathological process. Many TRT clinic patients fall into this category. The clinic’s evaluation will typically document low-normal testosterone, identify symptoms that cluster with the patient’s chief complaints, and recommend treatment under a clinical framework that emphasizes optimization rather than disease treatment. Whether the resulting treatment produces benefit beyond placebo response, regression to the mean, and the substantial nonspecific effects of being treated by an attentive clinician is a question the clinical evidence has not adequately answered.
The commercial dynamics of the sector reward expansion of the treatment-eligible population in ways that conventional fee-for-service medicine does not. A clinic that operates on a subscription model—with monthly fees covering medication, monitoring, and access—has economic incentive to recruit and retain patients across the broadest plausible eligibility range. The clinics that have scaled most aggressively, including several with dozens of locations across multiple states, have been targets of private equity rollups whose investment theses depend on continued expansion of the patient base. The financial logic of the sector has begun to resemble the dental service organization model, with similar implications for clinical practice patterns and corporate influence over prescribing decisions.
There is a parallel question about whether the conventional medical system has been failing the patient population that TRT clinics serve. The men presenting to these clinics are, in many cases, frustrated with primary care evaluations that produced no actionable diagnosis, with health systems that allocate ten-minute appointment slots to complex symptom presentations, and with a clinical culture that has historically been dismissive of male midlife symptom complexes that don’t fit into specific diagnostic categories. The clinics offer something the conventional system does not: extended evaluation, comprehensive lab work, structured follow-up, and a therapeutic intervention to discuss. Whether the intervention itself is appropriate is a clinical question. Whether the model of care that surrounds it meets a need the conventional system fails to meet is a different question, and the answer is more interesting.
Telehealth platforms have transformed the geography of TRT delivery in ways that have outpaced regulation. Companies like Hims, Roman, and several specialty TRT-focused platforms have built scaled prescribing operations that connect patients with licensed clinicians across state lines, offer convenient lab testing, and ship medications directly to patients’ homes. The convenience is substantial. The clinical depth is variable. The regulatory framework, which still assumes that prescribing relationships involve geographic proximity and ongoing in-person evaluation, has not adequately adapted to this delivery model. State medical boards have begun investigating individual cases, but the structural question of how cross-state telehealth prescribing should be regulated remains unsettled.
The pediatric and adolescent dimension is one that the broader hormone optimization sector has begun to engage uncomfortably. Some clinics have begun marketing services to younger patients, including men in their twenties and thirties whose testosterone levels are within population norms but who present with symptoms the marketing materials suggest may benefit from intervention. The clinical case for treating men under 35 is considerably weaker than the case for treating men over 50, and the long-term effects of androgen administration in younger patients are not well characterized. Whether the sector self-regulates to avoid this expansion, or whether external regulatory pressure will eventually be required, is unclear.
There is a counterintuitive finding from the public health research on testosterone prescribing that bears noting. In states with restrictive scope-of-practice rules that limit nurse practitioner prescribing of controlled substances, Health Affairs research has documented lower rates of testosterone prescribing without clear differences in clinical outcomes. The finding suggests that some fraction of contemporary testosterone prescribing reflects supply-induced demand rather than unmet clinical need—the prescribing rises to fill the available prescriber capacity, rather than being driven by underlying patient pathology. The implications for how the broader scope-of-practice regulatory architecture interacts with hormone therapy are worth thinking through carefully.
What the TRT clinic sector reveals, when one looks at it across the past two decades, is the trajectory that the broader hormone optimization and longevity medicine sector is likely to follow. A specialty emerges around a specific medication, scales through marketing and patient self-identification, professionalizes as private equity capital flows in, faces regulatory and clinical scrutiny without being substantially constrained by it, and ultimately becomes a settled feature of the medical landscape that operates parallel to the conventional system without being absorbed by it. The peptide clinics, the longevity medicine practices, and the various other adjacent sectors are several years behind on this trajectory but are following the same arc. Whether the arc bends toward integration with the conventional system, or whether the parallel medical economy continues to grow indefinitely as a permanent feature of American healthcare, will depend on regulatory choices and on the conventional system’s willingness to engage with patient populations it has historically dismissed. So far, neither side has shown any urgency about closing the gap.
